{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-012056","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2022-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.594745+00:00","generated_at":"2026-06-26T14:24:22.627033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year","bullets":["BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.","Net loss $32.9M ($1.25/share) for FY2021 vs $55.2M ($5.15/share) in FY2020.","Cash $104.5M at year-end; projected runway into Q2 2023; plus $9.7M non-dilutive in early 2022.","Positive Phase 3 CANDLE for rVVC (65.4% vs 53.1% placebo, p=0.02); sNDA filing Q2 2022.","Initiating MARIO Phase 3 for invasive candidiasis; Orphan Medicinal Product Designation from EMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-012056","json":"https://secwatch.observer/filing/0001564590-22-012056.json","markdown":"https://secwatch.observer/filing/0001564590-22-012056.md","text":"https://secwatch.observer/filing/0001564590-22-012056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/0001564590-22-012056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/scyx-8k_20220329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T14:24:22.627033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}